Introduction: Physicians have largely studied the cutaneous involvement of coronavirus disease 2019 (COVID-19), but only few reports have focused on telogen effluvium (TE) as a possible sequela of COVID-19. We assessed 14 cases of hair loss occurring after SARS-CoV-2 infection using trichoscopy and trichogram to investigate patterns related to COVID-19. Furthermore, we discussed possible mechanisms involved in COVID-19 TE. Case Presentation: Fourteen individuals were referred to our post-COVID-19 dermatology office complaining acute hair loss after SARS-CoV-2 infection. Clinical evaluation included pull test, trichoscopy, and trichogram. CO-VID-19 TE occurred after a median of 2 months (range 1–3 months) following SARS-CoV-2 infection. The median duration of hair loss was 5 months (range 1–6 months). Trichoscopy showed variable but typical TE patterns. Trichogram showed different telogen/anagen ratio depending on the interval between onset of hair loss and trichological visit. Discussion/Conclusion: Our cases showed TE between 1 and 3 months after the onset of SARS-CoV-2 infection, thus earlier than classic TE. Trichoscopic features and trichogram showed no variations from classic TE. Different pathogenetic mechanisms including pro-inflammatory cytokines and direct viral damage on the hair follicle can be hypothesized; further studies on a larger sample are needed to better understand this condition.

1.
Daneshgaran
G
,
Dubin
DP
,
Gould
DJ
.
Cutaneous manifestations of COVID-19: an evidence-based review
.
Am J Clin Dermatol
.
2020 Oct
;
21
(
5
):
627
39
. .
2.
Klingman
A
.
Pathologic dynamics of human hair loss. I. Telogen effluvium
.
Arch Dermatol
.
1961 Feb
;
83
:
175
98
.
3.
Rivetti
N
,
Barruscotti
S
.
Management of telogen effluvium during the COVID-19 emergency: psychological implications
.
Dermatol Ther
.
2020 Jul
;
33
(
4
):
e13648
. .
4.
Turkmen
D
,
Altunisik
N
,
Sener
S
,
Colak
C
.
Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire
.
Dermatol Ther
.
2020 Nov
;
33
(
6
):
e13923
. .
5.
Domínguez-Santás
M
,
Haya-Martínez
L
,
Fernández-Nieto
D
,
Jiménez-Cauhé
J
,
Suárez-Valle
A
,
Díaz-Guimaraens
B
.
Acute telogen effluvium associated with SARS-CoV-2 infection
.
Aust J Gen Pract
.
2020 Aug 26
;
49
:
49
. .
6.
Mieczkowska
K
,
Deutsch
A
,
Borok
J
,
Guzman
AK
,
Fruchter
R
,
Patel
P
,
Telogen effluvium: a sequela of COVID-19
.
Int J Dermatol
.
2021 Jan
;
60
(
1
):
122
4
. .
7.
Giulio
R
,
Federico
D
,
Anna
C
,
Radi
G
,
Bianchelli
T
,
Molinelli
E
,
Telogen effluvium related to post severe Sars-Cov-2 Infection: clinical aspects and our management experience
.
Dermatol Ther
.
2021 Jan
;
34
(
1
):
e14547
.
8.
Tosti
A
,
Misciali
C
,
Bardazzi
F
,
Fanti
PA
,
Varotti
C
.
Telogen effluvium due to recombinant interferon alpha-2b
.
Dermatology
.
1992
;
184
(
2
):
124
5
. .
9.
Mandt
N
,
Geilen
CC
,
Wrobel
A
,
Gelber
A
,
Kamp
H
,
Orfanos
CE
,
Interleukin-4 induces apoptosis in cultured human follicular keratinocytes, but not in dermal papilla cells
.
Eur J Dermatol
.
2002 Sep–Oct
;
12
(
5
):
432
8
.
10.
Xiong
Y
,
Harmon
CS
.
Interleukin-1beta is differentially expressed by human dermal papilla cells in response to PKC activation and is a potent inhibitor of human hair follicle growth in organ culture
.
J Interferon Cytokine Res
.
1997 Mar
;
17
(
3
):
151
7
. .
11.
Ulrich
H
,
Pillat
MM
,
Tárnok
A
.
Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective
.
Cytometry A
.
2020 Jul
;
97
(
7
):
662
7
. .
12.
Wei
KC
,
Huang
MS
,
Chang
TH
.
Dengue virus infects primary human hair follicle dermal papilla cells
.
Front Cell Infect Microbiol
.
2018 Aug
;
8
:
268
. .
13.
Karthik
K
,
Senthilkumar
TMA
,
Udhayavel
S
,
Raj
GD
.
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
.
Hum Vaccin Immunother
.
2020 Dec 1
;
16
(
12
):
1
6
. .
14.
Trüeb
RM
,
Dutra Rezende
H
,
Gavazzoni Dias
MFR
.
What can the hair tell us about COVID-19?
Exp Dermatol
.
2021 Feb
;
30
(
2
):
288
90
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.